| Original language | English |
|---|---|
| Pages (from-to) | 655-667 |
| Number of pages | 13 |
| Journal | Pharmacoeconomics |
| Volume | 37 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 2019 |
Keywords
- PHASE-III TRIAL
- WEEKLY PACLITAXEL
- VINFLUNINE PLUS
- SUPPORTIVE CARE
- OPEN-LABEL
- CARCINOMA
- MONOTHERAPY
- MULTICENTER
- DOCETAXEL
Cite this
}
Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer : An Evidence Review Group Perspective of a NICE Single Technology Appraisal. / Grimm, Sabine E.; Armstrong, Nigel; Ramaekers, Bram L. T.; Pouwels, Xavier; Lang, Shona; Petersohn, Svenja; Riemsma, Rob; Worthy, Gillian; Stirk, Lisa; Ross, Janine; Kleijnen, Jos; Joore, Manuela A.
In: Pharmacoeconomics, Vol. 37, No. 5, 05.2019, p. 655-667.Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer
T2 - An Evidence Review Group Perspective of a NICE Single Technology Appraisal
AU - Grimm, Sabine E.
AU - Armstrong, Nigel
AU - Ramaekers, Bram L. T.
AU - Pouwels, Xavier
AU - Lang, Shona
AU - Petersohn, Svenja
AU - Riemsma, Rob
AU - Worthy, Gillian
AU - Stirk, Lisa
AU - Ross, Janine
AU - Kleijnen, Jos
AU - Joore, Manuela A.
PY - 2019/5
Y1 - 2019/5
KW - PHASE-III TRIAL
KW - WEEKLY PACLITAXEL
KW - VINFLUNINE PLUS
KW - SUPPORTIVE CARE
KW - OPEN-LABEL
KW - CARCINOMA
KW - MONOTHERAPY
KW - MULTICENTER
KW - DOCETAXEL
U2 - 10.1007/s40273-018-0723-5
DO - 10.1007/s40273-018-0723-5
M3 - Review article
VL - 37
SP - 655
EP - 667
JO - Pharmacoeconomics
JF - Pharmacoeconomics
SN - 1170-7690
IS - 5
ER -